These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Long-term follow-up of postmyocardial infarction patients with ventricular tachycardia or ventricular fibrillation treated with amiodarone. Strasberg B, Kusniec J, Zlotikamien B, Mager A, Sclarovsky S. Am J Cardiol; 1990 Sep 15; 66(7):673-8. PubMed ID: 2399883 [Abstract] [Full Text] [Related]
4. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F, Ardissino D, Califf RM, Granger CB, Ohman EM, Alexander JH. Crit Care Med; 2011 Jan 15; 39(1):78-83. PubMed ID: 20959785 [Abstract] [Full Text] [Related]
5. Electrophysiologic predictors of long-term clinical outcome with amiodarone for refractory ventricular tachycardia secondary to coronary artery disease. Yazaki Y, Haffajee CI, Gold RL, Bishop RL, Alpert JS. Am J Cardiol; 1987 Aug 01; 60(4):293-7. PubMed ID: 3618488 [Abstract] [Full Text] [Related]
6. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). Piccini JP, Hranitzky PM, Kilaru R, Rouleau JL, White HD, Aylward PE, Van de Werf F, Solomon SD, Califf RM, Velazquez EJ. Am J Cardiol; 2008 Dec 01; 102(11):1427-32. PubMed ID: 19026290 [Abstract] [Full Text] [Related]
7. Lessons from antiarrhythmic trials involving class III antiarrhythmic drugs. Yap YG, Camm AJ. Am J Cardiol; 1999 Nov 04; 84(9A):83R-89R. PubMed ID: 10568665 [Abstract] [Full Text] [Related]
14. Prospective evaluation of a discriminant function for prediction of recurrent symptomatic ventricular tachycardia or ventricular fibrillation in coronary artery disease patients receiving amiodarone and having inducible ventricular tachycardia at electrophysiologic study. Klein LS, Fineberg N, Heger JJ, Miles WM, Kammerling JM, Chang MS, Zipes DP, Prystowsky EN. Am J Cardiol; 1988 May 01; 61(13):1024-30. PubMed ID: 3364357 [Abstract] [Full Text] [Related]
15. [Prediction of long-term efficacy of amiodarone for refractory ventricular tachycardia: clinical significance of electrophysiologic study and Holter monitoring]. Tsuchiya M, Kasanuki H, Ohnishi S, Hosoda S. J Cardiol; 1996 Nov 01; 28(5):267-76. PubMed ID: 8953400 [Abstract] [Full Text] [Related]
16. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Cairns JA, Connolly SJ, Roberts R, Gent M. Lancet; 1997 Mar 08; 349(9053):675-82. PubMed ID: 9078198 [Abstract] [Full Text] [Related]
17. Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: results of long-term follow-up. Schläpfer J, Rapp F, Kappenberger L, Fromer M. J Am Coll Cardiol; 2002 Jun 05; 39(11):1813-9. PubMed ID: 12039497 [Abstract] [Full Text] [Related]
18. Predictors of mortality in patients with sustained ventricular tachycardias or ventricular fibrillation and depressed left ventricular function: importance of beta-blockade. Szabó BM, Crijns HJ, Wiesfeld AC, van Veldhuisen DJ, Hillege HL, Lie KI. Am Heart J; 1995 Aug 05; 130(2):281-6. PubMed ID: 7631608 [Abstract] [Full Text] [Related]